gracial
aspen pharma trading limited - dezogestrelis/etinilestradiolis+dezogestrelis/etinilestradiolis - tabletės - 25 µg/40 µg + 125 µg/30 µg - desogestrel and ethinylestradiol
novofem
novo nordisk a/s - estradiolis+estradiolis/noretisterono acetatas - plėvele dengtos tabletės - 1 mg + 1 mg/1 mg - norethisterone and estrogen
activelle
novo nordisk a/s - estradiolis/noretisteronas - plėvele dengtos tabletės - 1 mg/0,5 mg - norethisterone and estrogen
rosuvastatin teva pharma
teva b.v. - rozuvastatinas - plėvele dengtos tabletės - 20 mg; 10 mg; 5 mg - rosuvastatin
rosuvastatin krka
krka, d.d., novo mesto - rozuvastatinas - plėvele dengtos tabletės - 40 mg; 20 mg; 15 mg; 10 mg; 5 mg; 30 mg - rosuvastatin
roswera
krka, d.d., novo mesto - rozuvastatinas - plėvele dengtos tabletės - 40 mg; 30 mg; 20 mg; 15 mg; 10 mg; 5 mg - rosuvastatin
estrofem
novo nordisk a/s - estradiolis - plėvele dengtos tabletės - 1 mg; 2 mg - estradiol
lorviqua
pfizer europe ma eeig - lorlatinib - karcinoma, nesmulkiųjų ląstelių skausmas - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
rosuvastatin accord
accord healthcare b.v. - rozuvastatinas - plėvele dengtos tabletės - 40 mg; 10 mg; 5 mg; 20 mg - rosuvastatin
rosuvastatin/ezetimibe teva
teva b.v. - rozuvastatinas/ezetimibas - plėvele dengtos tabletės - 10 mg/10 mg - rosuvastatin and ezetimibe